Composition: Ofloxacin IP 200mg + Ornidazole 500 mg (tablets). The rationale for the combination is complementary action: Ofloxacin (fluoroquinolone antibacterial) and Ornidazole (nitroimidazole antimicrobial).
Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Ornidazole is a nitroimidazole active against susceptible anaerobic bacteria and protozoa such as Entamoeba histolytica and Giardia lamblia.
AEROFLOX-DZ is a prescription medicine from Aerochem Neutron's antibiotic range, for use on the prescription of a registered medical practitioner..
· Contains Ofloxacin IP 200mg + Ornidazole 500 mg
· Ofloxacin — a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV
· Ornidazole — a nitroimidazole active against susceptible anaerobic bacteria and protozoa such as Entamoeba histolytica and Giardia lamblia
· Presented as tablets
Prescription-only medicine· Acute and chronic infective diarrhoea and dysentery of mixed bacterial/protozoal origin
· Gastrointestinal infections, including amoebiasis
· Enteric fever, where the combination is clinically appropriate
· Other indications as per the approved prescribing information
· Note: indications reflect established uses of the individual molecules; confirm against the CDSCO-approved label for this fixed-dose combination
Safety
· Contraindicated in patients with known hypersensitivity to any component.
· Fluoroquinolones carry warnings for tendinitis and tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, dysglycaemia and aortic aneurysm risk, and can worsen myasthenia gravis; reserve for situations where they are clearly appropriate and avoid in pregnancy and in children unless benefits outweigh risks.
· Nitroimidazoles may cause metallic taste, gastrointestinal upset and, rarely, peripheral neuropathy or seizures; avoid alcohol during and shortly after therapy and use caution in the first trimester of pregnancy.
· Refer to the full prescribing information for all contraindications and interactions.
Clinical Rationale: The mechanisms and labelled uses of ofloxacin described here follow the US prescribing information (DailyMed); the EMA 2018 fluoroquinolone review restricted these agents because of disabling and potentially long-lasting adverse effects, which is why use should be limited to cases where they are clearly appropriate; antibiotic choice should follow local resistance data and the WHO AWaRe antibiotic book. Evidence summary for Ornidazole: reference verification pending. Use of the combination should follow the CDSCO-approved label for this fixed-dose combination.
References
· DailyMed (US NLM) prescribing information – ofloxacin: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OFLOXACIN
· EMA – Quinolone and fluoroquinolone medicines referral (2018): https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products
· WHO AWaRe (Access, Watch, Reserve) antibiotic book (2022): https://www.who.int/publications/i/item/9789240062382
· Reference verification pending for: Ornidazole
Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.
Review verified active composition, strength, dosage form, and packaging details on this page.
View SpecificationsRequest formulation literature, technical specifications, or product communication from our commercial team.
Submit Product EnquiryConnect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.
Commercial EnquiryThis product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.
Request information about AEROFLOX-DZ for professional use.